Article thumbnail

VEGF Promotes Malaria-Associated Acute Lung Injury in Mice

By Sabrina Epiphanio, Marta G. Campos, Ana Pamplona, Daniel Carapau, Ana C. Pena, Ricardo Ataíde, Carla A. A. Monteiro, Nuno Félix, Artur Costa-Silva, Claudio R. F. Marinho, Sérgio Dias and Maria M. Mota


The spectrum of the clinical presentation and severity of malaria infections is broad, ranging from uncomplicated febrile illness to severe forms of disease such as cerebral malaria (CM), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), pregnancy-associated malaria (PAM) or severe anemia (SA). Rodent models that mimic human CM, PAM and SA syndromes have been established. Here, we show that DBA/2 mice infected with P. berghei ANKA constitute a new model for malaria-associated ALI. Up to 60% of the mice showed dyspnea, airway obstruction and hypoxemia and died between days 7 and 12 post-infection. The most common pathological findings were pleural effusion, pulmonary hemorrhage and edema, consistent with increased lung vessel permeability, while the blood-brain barrier was intact. Malaria-associated ALI correlated with high levels of circulating VEGF, produced de novo in the spleen, and its blockage led to protection of mice from this syndrome. In addition, either splenectomization or administration of the anti-inflammatory molecule carbon monoxide led to a significant reduction in the levels of sera VEGF and to protection from ALI. The similarities between the physiopathological lesions described here and the ones occurring in humans, as well as the demonstration that VEGF is a critical host factor in the onset of malaria-associated ALI in mice, not only offers important mechanistic insights into the processes underlying the pathology related with malaria but may also pave the way for interventional studies

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1983). [P. falciparum and P. malariae malaria complicated by pulmonary edema with disseminated intravascular coagulation].
  2. (2008). Acute lung injury and acute respiratory distress syndrome in malaria.
  3. (2007). Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies.
  4. (1998). Acute Plasmodium chabaudi chabaudi malaria infection induces antibodies which bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro.
  5. (1999). Acute pulmonary edema complicating ovale malaria.
  6. (2005). Acute respiratory distress syndrome due to vivax malaria: case report and literature review.
  7. (2007). Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg
  8. (2004). Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization.
  9. (2008). Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria.
  10. (2007). Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children.
  11. (2006). Clinical implications for vascular endothelial growth factor in the lung: friend or foe?
  12. (2005). Cytoprotection of heme oxygenase-1/carbon monoxide in lung injury.
  13. (2007). Defect in early lung defence against Pseudomonas aeruginosa in DBA/2 mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naive macrophages.
  14. Elevated levels of vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor (VEGFR)-2 in human malaria.
  15. (2006). Geneexpression profiling discriminates between cerebral malaria (CM)-susceptible mice and CM-resistant mice.
  16. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
  17. (2007). Genetic linkage and association analyses for trait mapping in Plasmodium falciparum.
  18. (2007). Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria.
  19. (2006). Hypertension and maternal-fetal conflict during placental malaria.
  20. (2005). Immunological processes in malaria pathogenesis.
  21. (2006). Insights into the immunopathogenesis of malaria using mouse models.
  22. (2000). Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema.
  23. (2002). Malaria and the lung.
  24. (2007). Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease.
  25. (2007). Malarial anemia: of mice and men.
  26. (1997). Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.
  27. (2007). Noninvasive ventilation in Plasmodium vivax related ALI/ARDS.
  28. (2007). P. vivax malaria complicated by shock and ARDS.
  29. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.
  30. (2008). Parasite burden and CD36-mediated sequestration are determinants of acute lung injury in an experimental malaria model.
  31. (2004). Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev 17: 509–539, table of contents.
  32. (1992). Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice.
  33. (2008). Plasma IP10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India.
  34. (1983). Plasmodium berghei: a mouse model for the ‘‘sudden death’’ and ‘‘malarial lung’’ syndromes.
  35. (2008). Pregnancy outcome and placenta pathology in Plasmodium berghei ANKA infected mice reproduce the pathogenesis of severe malaria in pregnant women.
  36. (1985). Pulmonary damage associated with falciparum malaria: a report of ten cases.
  37. (1972). Pulmonary function studies in Plasmodium falciparum malaria.
  38. (2006). Pulmonary manifestations of malaria: recognition and management.
  39. (2001). Role of CD40-CVD40L in mouse severe malaria.
  40. (2007). Severe malaria increases the list of heme oxygenase-1-protected diseases.
  41. (1996). The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency.
  42. (2007). The relevance of host genes in malaria.
  43. (2006). The silent path to thousands of merozoites: the Plasmodium liver stage.
  44. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
  45. (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis.
  46. (1999). Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
  47. (2001). Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome.
  48. (1997). Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
  49. (1991). Vascular permeability factor: a unique regulator of blood vessel function.